NL INDUSTRIES ANNOUNCES QUARTERLY DIVIDEND FOR THE FOURTH QUARTER OF 2025 AT $.09 PER SHARE

NLI HOLDINGS, INC. (NL) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ ​ ​ ​ ​ ​ ​ ​ NLI REPORTS SECOND QUARTER 2026 RESULTS ​ DALLAS, TEXAS – August 5, 2026 – NLI Holdings, Inc. (NYSE: NL) reported net income attributable to NLI stockholders of $9.0 million, or $.18 per share, in the second quarter of 2026 compared to $.3 million, or $.01 per sha

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

Lockheed Martin is investing $420 million to expand its Camden, Arkansas facility, creating 650 jobs over five years. The expansion will boost production of PAC-3, THAAD, and PrSM platforms. The company has increased operations in Arkansas, including a new Munitions Acceleration Center to quadruple THAAD interceptor production.

Shinhan Investment & Securities raised POSCO FUTURE M's target price to 200,000 won, citing growth in LFP cathode sales. The company expects cathode shipments to double by 2027, with LFP exceeding 50% of sales. POSCO FUTURE M's Q3 sales and operating profit rose 23% and 207% YoY, respectively, driven by energy materials unit.

Blackstone and Canadian pension funds will invest $3.1 billion to buy 49.9% of Mitsubishi Corp.'s stake in LNG Canada. Mitsubishi retains 15% of the LNG export plant, which is expanding capacity to 28 million tonnes per year. LNG Canada is a $40 billion project led by Shell, with other partners including Petronas, PetroChina, and Korea Gas.

Freedom Broker maintained its Hold rating on Merck & Co but raised its price target to $140 from $125. This implies a 5.6% downside from the Nov 2 close of $148.36. Recent analyst price targets for Merck range from $140 to $180.